 |
Title
|
|
|
|
Phase 
|
|
|
|
Protocol IDs
|
|
|
| |
Combination Chemotherapy With or Without Monoclonal Antibody Therapy
Followed by Stem Cell Transplant in Treating Patients With Acute Myeloid
Leukemia
|
|
|
|
Phase III
|
|
|
|
ECOG-1900
E1900, NCT00049517
|
|
| |
Cytarabine and Daunorubicin With or Without Gemtuzumab Ozogamicin Followed By High-Dose Cytarabine Followed By Either Gemtuzumab Ozogamicin or No Additional Therapy in Treating Patients With Previously Untreated De Novo Acute Myeloid Leukemia
|
|
|
|
Phase III
|
|
|
|
SWOG-S0106
S0106, NCT00085709
|
|
| |
Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia
|
|
|
|
Phase III
|
|
|
|
COG-AAML0531
AAML0531, NCT00372593
|
|
| |
Comparing Peripheral Blood Stem Cell Transplantation Versus Bone Marrow Transplantation in Individuals With Hematologic Cancers
|
|
|
|
Phase III
|
|
|
|
418
BMTCTN-0201, NCT00075816
|
|
| |
Combination Chemotherapy With or Without Gemtuzumab Followed By Tretinoin, Mercaptopurine, and Methotexate or Observation in Treating Patients With Acute Promyelocytic Leukemia
|
|
|
|
Phase III
|
|
|
|
SWOG-S0521
S0521, NCT00492856
|
|
| |
Study of Low-Dose Cytarabine in Combination With Arsenic Trioxide, Compared With Low-Dose Cytarabine Alone, for the Treatment of Elderly Patients With Acute Myeloid Leukemia
|
|
|
|
Phase III
|
|
|
|
C18477/3059/AM/US-CA
NCT00513305
|
|
| |
Daunorubicin, Cytarabine, and Midostaurin in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
|
|
|
|
Phase III
|
|
|
|
CALGB-10603
CALGB 10603, CALGB-10603, EUDRACT-2006-006852-37, NCT00651261
|
|
| |
Study of Clofarabine & Cytosine Arabinoside Therapy for Older Adults With Acute Myeloid Leukemia
|
|
|
|
Phase II, Phase I
|
|
|
|
F040114019
UAB 0341, NCT00081822
|
|
| |
DT388IL3 Fusion Protein in Treating Patients With Acute Myeloid Leukemia or Accelerated Phase or Blastic Phase Chronic Myeloid Leukemia
|
|
|
|
Phase II, Phase I
|
|
|
|
S-WHITE-22304
S-WHITE-050047, NCT00397579
|
|
| |
Vorinostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia
|
|
|
|
Phase II, Phase I
|
|
|
|
NYCC-6898
6898, NCI-6898, NCT00392353
|
|
